dexamethasone sodium phosphate

The TGA does not publish a reason for a shortage, so Voxsanity cannot show one. Nothing on this page is an explanation of why supply is affected — that information is not in the source and is not inferred here.

This is national information. The TGA records shortages for Australia as a whole. There is no state, territory or pharmacy-level stock information in this data, and Voxsanity cannot tell you whether a particular pharmacy has a medicine in stock. Your pharmacist can.

dexamethasone sodium phosphate is subsidised on the PBS. The active ingredient is on the current Pharmaceutical Benefits Scheme, so it is a medicine dispensed under subsidy across Australia rather than one supplied through a narrower route. That is a fact about how widely it is used, not a rating of how serious this shortage is — the TGA's own impact rating above is the only severity statement on this page, and this does not change it.

A PBS listing is recorded against the active ingredient, while a shortage is usually reported against particular brands, strengths or pack sizes. So a subsidised alternative brand of the same ingredient may still be available even where a shortage is open. Your pharmacist can tell you what is in stock and can discuss substitutions with your prescriber.

PBS-subsidised for: Retinal Vein Occlusion and Diabetic Macular Oedema, Uveitis. That is what the Pharmaceutical Benefits Scheme records the subsidy for dexamethasone sodium phosphate against, not the full range of conditions it is used for. A medicine subsidised under an indication Voxsanity has not mapped to a condition page, or used for a condition without a PBS subsidy for it, does not appear here — so this list understates what the medicine is used for and can never overstate it.

Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.